Key Takeaway: Upstream Bio has reported its financial results for Q2 2026, highlighting significant progress towards the initiation of Phase 3 trials in Q1 2027. The trials aim to provide best-in-class efficacy for treatments in severe asthma and CRSwNP. Additionally, the company has completed enrollment in its Phase 2 trial for COPD, with data expected soon.
Focus on best-in-class efficacy with quarterly dosing.
Successful completion of enrollment in Phase 2 trial.
BiopharmaWatch Analysis
From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+74%
120-day peak, hindsight
Typical move
21.5%
average across 3 past catalysts
Cash runway
~19 mo
Low dilution risk
Lead asset
Verekitug
Phase 2 · Chronic Obstructive Pulmonary Disease
Full Press Release Details
– Company rapidly advancing toward Q1 2027 initiation of Phase 3 trials designed to deliver best-in-class efficacy with convenient quarterly dosing in both severe asthma and CRSwNP; End-of-Phase 2 interactions with FDA on track – – Completed enrollment in Phase 2 trial in COPD; data expected in the
Frequently Asked Questions
What are the key highlights from Upstream Bio's Q2 2026 report?
The report highlights progress towards Phase 3 trials and completion of Phase 2 trial enrollment.
When is Upstream Bio initiating Phase 3 trials?
Upstream Bio plans to initiate Phase 3 trials in Q1 2027.
What conditions are targeted in Upstream Bio's Phase 3 trials?
The Phase 3 trials target severe asthma and CRSwNP.
What is the status of the Phase 2 trial in COPD?
Enrollment in the Phase 2 trial for COPD has been completed, with data expected soon.